MX346748B - (2s, 3r)-n-2(2-((3-pirimidil)metil)-1-azabiciclo[2.2.2]oct-3-il)be nzofuran-2-carboxamida, formas salinas novedosas, y sus metodos de uso. - Google Patents

(2s, 3r)-n-2(2-((3-pirimidil)metil)-1-azabiciclo[2.2.2]oct-3-il)be nzofuran-2-carboxamida, formas salinas novedosas, y sus metodos de uso.

Info

Publication number
MX346748B
MX346748B MX2012009258A MX2012009258A MX346748B MX 346748 B MX346748 B MX 346748B MX 2012009258 A MX2012009258 A MX 2012009258A MX 2012009258 A MX2012009258 A MX 2012009258A MX 346748 B MX346748 B MX 346748B
Authority
MX
Mexico
Prior art keywords
methods
azabicyclo
pyridinyl
carboxamide
oct
Prior art date
Application number
MX2012009258A
Other languages
English (en)
Inventor
Merouane Bencherif
Lan Miao
Gregory J Gatto
Julio A Munoz
John Genus
Gary Maurice Dull
Anatoly A Mazurov
Lisa Benson
Nicolai Fedorov
Kristen G Jordan
Jacob Mathew
Inigo Pfeiffer
Sondra Pfeiffer
Teresa Y Phillips
Original Assignee
Targacept Inc *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39945177&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX346748(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Targacept Inc * filed Critical Targacept Inc *
Publication of MX346748B publication Critical patent/MX346748B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Abstract

La presente invención describe (2S, 3R)-N-(2-((3-piridinil) metil)-1-azabiciclo [2 .2 .2] oct-3-iI) benzofuran-2-carboxamida, sus formas salinas novedosas, métodos para su preparación, intermedios novedosos y métodos para tratar una amplia variedad de condiciones y trastornos, que incluyen aquellos asociados con disfunción de los sistemas nervosos central y autonómico.
MX2012009258A 2007-08-02 2008-08-01 (2s, 3r)-n-2(2-((3-pirimidil)metil)-1-azabiciclo[2.2.2]oct-3-il)be nzofuran-2-carboxamida, formas salinas novedosas, y sus metodos de uso. MX346748B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95361307P 2007-08-02 2007-08-02
US95361407P 2007-08-02 2007-08-02
US95361007P 2007-08-02 2007-08-02
US97165407P 2007-09-12 2007-09-12
PCT/US2008/071872 WO2009018505A1 (en) 2007-08-02 2008-08-01 (2s,3r)-n-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof

Publications (1)

Publication Number Publication Date
MX346748B true MX346748B (es) 2017-03-29

Family

ID=39945177

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2012009257A MX346451B (es) 2007-08-02 2008-08-01 (2s, 3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)ben zofuran-2-carboxamida, formas salinas novedosas, y sus metodos de uso.
MX2012009258A MX346748B (es) 2007-08-02 2008-08-01 (2s, 3r)-n-2(2-((3-pirimidil)metil)-1-azabiciclo[2.2.2]oct-3-il)be nzofuran-2-carboxamida, formas salinas novedosas, y sus metodos de uso.
MX2010001293A MX2010001293A (es) 2007-08-02 2008-08-01 Tratamiento con ligandos alfa 7-selectivos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2012009257A MX346451B (es) 2007-08-02 2008-08-01 (2s, 3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)ben zofuran-2-carboxamida, formas salinas novedosas, y sus metodos de uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2010001293A MX2010001293A (es) 2007-08-02 2008-08-01 Tratamiento con ligandos alfa 7-selectivos.

Country Status (35)

Country Link
US (6) US20110124678A1 (es)
EP (6) EP2484363A1 (es)
JP (4) JP5358573B2 (es)
KR (2) KR20100063043A (es)
CN (4) CN101784273B (es)
AR (1) AR067775A1 (es)
AU (3) AU2008283807B2 (es)
BR (2) BRPI0814889A2 (es)
CA (2) CA2694510A1 (es)
CL (3) CL2008002271A1 (es)
CO (2) CO6260081A2 (es)
CY (1) CY1113561T1 (es)
DK (2) DK2182949T3 (es)
EC (2) ECSP10010007A (es)
ES (3) ES2606752T3 (es)
HK (1) HK1140968A1 (es)
HR (1) HRP20130286T1 (es)
HU (1) HUE030387T2 (es)
IL (1) IL218976A0 (es)
ME (1) ME01508B (es)
MX (3) MX346451B (es)
MY (1) MY148002A (es)
NO (2) NO20100078L (es)
NZ (2) NZ582828A (es)
PE (3) PE20090566A1 (es)
PL (1) PL2182949T3 (es)
PT (1) PT2182949E (es)
RS (1) RS52743B (es)
RU (2) RU2012140148A (es)
SA (2) SA08290475B1 (es)
SI (1) SI2182949T1 (es)
TW (3) TW201402117A (es)
UY (1) UY31265A (es)
WO (2) WO2009018505A1 (es)
ZA (1) ZA201000719B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US20110098312A1 (en) * 2008-05-12 2011-04-28 Targacept ,Inc Methods for preventing the development of retinopathy by the oral administration of nnr ligands
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
TWI558398B (zh) 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途
SA111320455B1 (ar) 2010-05-17 2014-10-16 Envivo Pharmaceuticals Inc صورة بلورية من (R)-7- كلورو -N- (كينوكليدين -3- يل) بنزو[b] ثيوفين -2- كربوكساميد هيدروكلوريد أحادي الهيدرات
WO2012015749A1 (en) * 2010-07-26 2012-02-02 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptor agonists in combination with acetylcholinesterase inhibitors
NZ707955A (en) 2010-09-23 2016-03-31 Abbvie Bahamas Ltd Monohydrate of an azaadamantane derivative
AU2012207499A1 (en) * 2011-01-18 2013-08-15 Targacept, Inc. Treatment of cognitive dysfunction in schizophrenia
MX2013008704A (es) 2011-01-27 2013-08-21 Novartis Ag Uso de activadores del receptor de acetil-colina nicotinico alfa-7.
SI3156056T1 (sl) 2011-03-18 2024-03-29 Alkermes Pharma Ireland Limited Farmacevtski sestavki, ki obsegajo estre sorbitana
BR112013023813A2 (pt) 2011-03-18 2016-12-13 Novartis Ag combinações de ativadores do receptor acetilcolina nicotínico alfa 7 e antagonistas de mglur5 para uso em dopamina induzida por discinesia na doença de parkinson
WO2012129262A1 (en) 2011-03-23 2012-09-27 Targacept, Inc. Treatment of attention deficit/hyperactivity disease
US20140128606A1 (en) 2011-06-30 2014-05-08 Toray Industries, Inc. Antipruritic agent
TW201311698A (zh) * 2011-08-22 2013-03-16 Targacept Inc 作為神經元菸鹼乙醯膽鹼受體配位體之１，４－二氮雜雙環［３．２．２］壬烷
JO3766B1 (ar) 2011-10-20 2021-01-31 Novartis Ag منشط مستقبل أسيتيل كولين الفا - 7 النيكوتيني
NZ630643A (en) 2012-03-19 2017-08-25 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising fatty acid esters
JP6333802B2 (ja) 2012-03-19 2018-05-30 アルカームス ファーマ アイルランド リミテッド ベンジルアルコールを含む医薬組成物
WO2013142202A1 (en) * 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
EP3666272A1 (en) 2012-05-08 2020-06-17 Forum Pharmaceuticals Inc. Use of encenicline in the treatment of cognitive impairment, alzheimer's disease, memory deficit
CA2885196C (en) 2012-09-19 2021-06-22 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
CA2894384C (en) 2012-12-11 2018-03-06 Novartis Ag Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
US20150313884A1 (en) 2013-01-15 2015-11-05 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
WO2014111751A1 (en) 2013-01-15 2014-07-24 Novartis Ag Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy
JP6338223B2 (ja) 2013-01-15 2018-06-06 ノバルティス アーゲー アルファ７ニコチン性アセチルコリン受容体アゴニストの使用
KR101879919B1 (ko) 2013-01-15 2018-07-18 노파르티스 아게 알파 7 니코틴성 아세틸콜린 수용체 작용물질의 용도
WO2014153424A1 (en) * 2013-03-19 2014-09-25 La Jolla Institute For Allergy And Immunology Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
RU2688233C2 (ru) 2014-03-20 2019-05-21 Алкермес Фарма Айэленд Лимитед Препараты арипипразола, имеющие повышенные скорости впрыска
MX2016013027A (es) 2014-04-04 2017-05-23 Del Mar Pharmaceuticals Uso de dianhidrogalactitol y analogos o derivados del mismo para tratar cancer de celulas no pequeñas del pulmon y cancer de ovario.
CN104288771B (zh) * 2014-09-30 2017-03-15 郑州大学第五附属医院 α7nAChR激动剂的新用途
EA201792443A1 (ru) 2015-05-06 2018-10-31 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния МОДУЛЯТОРЫ K-Ras
US9724340B2 (en) * 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
US10282666B1 (en) 2015-11-10 2019-05-07 Google Llc Coherency detection and information management system
RU2675111C2 (ru) * 2017-03-31 2018-12-17 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии" Способ стимуляции нейрогенеза в гиппокампе
MX2019012532A (es) 2017-04-20 2019-12-02 Univ California Moduladores de k-ras.
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203990A (en) 1979-04-30 1980-05-20 G. D. Searle & Co. Anti-diarrheal 2-substituted quinuclidines
EP0353189B1 (de) 1988-07-28 1994-01-12 Ciba-Geigy Ag Kupfer- und Nickeldihalogenidkomplexe, Verfahren zu deren Herstellung und deren Verwendung
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
EP0402056A3 (en) 1989-06-06 1991-09-04 Beecham Group p.l.c. Azabicyclic compounds, process for their preparation and pharmaceutical compositions containing them
JPH03135978A (ja) 1989-08-08 1991-06-10 Merck Sharp & Dohme Ltd 置換ピリジン、その製法、処方並びに痴呆症における使用法
IN173570B (es) 1989-11-23 1994-06-04 Pfizer
DK40890D0 (da) 1990-02-16 1990-02-16 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
EP0492903A1 (en) 1990-12-21 1992-07-01 MERCK SHARP & DOHME LTD. Substituted pyrazines, pyrimidines and pyridazines for use in the treatment of glaucoma
US5516785A (en) 1991-03-01 1996-05-14 University Of Florida Research Foundation, Incorporated Use of nicotinic analogs for treatment of degenerative diseases of the nervous system
US5212188A (en) 1992-03-02 1993-05-18 R. J. Reynolds Tabacco Company Method for treatment of neurodegenerative diseases
US5276043A (en) 1992-04-10 1994-01-04 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5977144A (en) 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
AU674541B2 (en) 1992-08-31 1997-01-02 University Of Florida Research Foundation, Inc. Anabaseine derivatives useful in the treatment of degenerative diseases of the nervous system
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
IL109451A0 (en) * 1993-04-29 1994-07-31 Zeneca Ltd Heterocyclic derivatives
AU7474794A (en) 1993-07-22 1995-02-20 E.I. Du Pont De Nemours And Company Arthropodicidal azacyclic heterocycles
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
US5510355A (en) 1994-09-06 1996-04-23 Bencherif; Merouane Depolarizing skeletal muscle relaxants
US5998404A (en) 1994-10-24 1999-12-07 Eli Lilly And Company Heterocyclic compounds and their use
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5824692A (en) 1995-01-06 1998-10-20 Lippiello; Patrick Michael Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US5616707A (en) 1995-01-06 1997-04-01 Crooks; Peter A. Compounds which are useful for prevention and treatment of central nervous system disorders
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
WO1996025160A1 (en) 1995-02-17 1996-08-22 Novo Nordisk A/S The use of heterocyclic compounds
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
EP0842172A1 (en) 1995-06-29 1998-05-20 Novo Nordisk A/S Novel substituted azacyclic or azabicyclic compounds
AU7083596A (en) 1995-09-22 1997-04-09 Novo Nordisk A/S Novel substituted azacyclic or azabicyclic compounds
US5712270A (en) 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5726189A (en) 1996-05-03 1998-03-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
ZA9711092B (en) 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
US5861423A (en) 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US5811442A (en) 1997-02-21 1998-09-22 Bencherif; Merouane Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow
CN1157392C (zh) 1997-05-30 2004-07-14 神经研究公司 在尼古丁ach受体上作为胆碱能配体的8-氮杂双环(3,2,1)辛-2-烯以及辛烷衍生物
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
ATE240331T1 (de) 1998-04-02 2003-05-15 Targacept Inc Azatricyclo(3.3.1.1)decanderivate und diese enthaltende phrmazeutische zubereitungen
US5952339A (en) 1998-04-02 1999-09-14 Bencherif; Merouane Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
JP4637351B2 (ja) 1998-06-01 2011-02-23 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 神経変性疾患の処置法
US6310043B1 (en) 1998-08-07 2001-10-30 Governors Of The University Of Alberta Treatment of bacterial infections
GB9821503D0 (en) 1998-10-02 1998-11-25 Novartis Ag Organic compounds
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US6734215B2 (en) 1998-12-16 2004-05-11 University Of South Florida Exo-S-mecamylamine formulation and use in treatment
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
FR2791678B1 (fr) * 1999-03-30 2001-05-04 Synthelabo Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
UA72632C2 (uk) 2000-06-27 2005-03-15 Лабораторіос С.А.Л.В.А.Т., С.А. Карбамати, похідні від арилалкіламінів
EP1381603A2 (en) 2000-08-18 2004-01-21 PHARMACIA & UPJOHN COMPANY Quinuclidine-substituedaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
WO2002016357A2 (en) 2000-08-18 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
AU2001284645A1 (en) 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
AU2001284646A1 (en) 2000-08-21 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
WO2002016355A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands
WO2002017358A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
MXPA03005583A (es) 2000-12-22 2004-05-05 Almirall Prodesfarma Ag Derivados de carbamato de quinuclidina y su uso como antagonistas m3.
US20020086871A1 (en) 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
NZ529426A (en) 2001-06-01 2005-07-29 Astrazeneca Ab Spiroazabicyclic heterocyclic amine ligands for nicotinic acetylcholine receptors useful in therapy
US6569865B2 (en) * 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
AR036040A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
US7109204B2 (en) 2001-08-01 2006-09-19 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003018585A1 (en) 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
JP2005504059A (ja) 2001-08-24 2005-02-10 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー 疾患を処置するための置換アリール７−アザ［２．２．１］ビシクロヘプタン
JP2005527472A (ja) 2001-09-12 2005-09-15 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 疾患治療のための置換された７−アザ［２．２．１］ビシクロヘプタン
CA2476681A1 (en) 2002-02-19 2003-08-28 Bruce N. Rogers Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
JP2005525357A (ja) 2002-02-20 2005-08-25 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー α７ニコチン性アセチルコリン受容体活性を伴うアザ二環式化合物
DE60333746D1 (de) 2002-04-18 2010-09-23 Astrazeneca Ab Thienylverbindungen
KR20040099447A (ko) 2002-04-18 2004-11-26 아스트라제네카 아베 푸릴 화합물
KR20040099446A (ko) 2002-04-18 2004-11-26 아스트라제네카 아베 헤테로시클릭 화합물
EP1542999A1 (en) 2002-08-01 2005-06-22 Pharmacia & Upjohn Company LLC 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
SE0202430D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
WO2004016608A1 (en) 2002-08-14 2004-02-26 Neurosearch A/S Novel quinuclidine derivatives and their use
SE0202465D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
EP2305664A1 (en) 2002-08-30 2011-04-06 Memory Pharmaceuticals Corporation Anabaseine derivatives useful in the treatment of neurodegeneratives diseases
BR0314485A (pt) 2002-09-25 2005-07-26 Memory Pharm Corp Indazóis, benzotiazóis e benzoisotiazóis, composto, composição farmacêutica, método desativação/estimulação seletiva de receptores nicotìnicos de a-7 em um mamìfero e método de tratamento e/ou prevenção de uma doença com os mesmos
WO2004039815A2 (en) 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Compounds having both alpha7 nachr agonist and 5ht antagonist activity for treatment of cns diseases
AU2003269413A1 (en) 2002-11-01 2004-05-25 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
EP2062595A1 (en) 2002-12-06 2009-05-27 The Feinstein Institute for Medical Research Inhibition of inflammation using alpha 7 receptor-binding cholinergic agonists
MXPA05006336A (es) 2002-12-11 2005-08-26 Pharmacia & Up John Company Ll Combinacion para el tratamiento de adhd.
BR0317110A (pt) 2002-12-11 2005-10-25 Pharmacia & Upjohn Co Llc Tratamento de doenças com combinações de agonistas do receptor nicotìnico da acetilcolina alfa 7 e outros compostos
US6917746B2 (en) 2002-12-17 2005-07-12 3M Innovative Properties Company Apparatus and method for creating a fiber optic circuit
US6777617B2 (en) 2002-12-30 2004-08-17 3M Innovative Properties Company Telecommunications terminal
ATE445618T1 (de) 2003-02-27 2009-10-15 Neurosearch As Neue diazabicyclische arylderivate
WO2005005435A1 (en) 2003-07-08 2005-01-20 Astrazeneca Ab Spiro ′1-azabicyclo ′2.2.2!octan-3,5′-oxazolidin -2′-one! derivatives with affinity to the alpha7 nicotinic acetylcholine receptor
NZ546414A (en) 2003-09-25 2009-07-31 Astrazeneca Ab Isotope and radio-labelled compounds that bind to nicotinic acetylcholine receptors
MXPA06004299A (es) 2003-10-21 2006-06-05 Astrazeneca Ab Derivados de arilespirofuropiridina.
US20050245531A1 (en) 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US7160876B2 (en) * 2003-12-22 2007-01-09 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20050137398A1 (en) 2003-12-22 2005-06-23 Jianguo Ji 3-Quinuclidinyl heteroatom bridged biaryl derivatives
US20050137217A1 (en) 2003-12-22 2005-06-23 Jianguo Ji Spirocyclic quinuclidinic ether derivatives
US20050137203A1 (en) 2003-12-22 2005-06-23 Jianguo Ji 3-quinuclidinyl amino-substituted biaryl derivatives
JP2007520527A (ja) * 2004-02-04 2007-07-26 ノイロサーチ アクティーゼルスカブ ニコチン性アセチルコリン受容体リガンドとしてのジアザ２環式アリール誘導体
JP2007534692A (ja) 2004-04-22 2007-11-29 メモリー・ファーマシューティカルズ・コーポレイション インドール、１ｈ−インダゾール、１，２−ベンズイソキサゾール、１，２−ベンゾイソチアゾール、ならびにその調製および使用
KR20070015607A (ko) 2004-05-07 2007-02-05 메모리 파마슈티칼스 코포레이션 1ｈ-인다졸, 벤조티아졸, 1,2-벤조이속사졸,1,2-벤조이소티아졸, 및 크로몬 및 그의 제조법 및 용도
WO2006045716A1 (en) * 2004-10-20 2006-05-04 Neurosearch A/S Novel diazabicyclic aryl derivatives and their medical use
BRPI0518949A2 (pt) 2004-12-15 2008-12-16 Astrazeneca Ab composto, uso de um composto, mÉtodo para induÇço da interrupÇço do hÁbito de fumar, composiÇço farmacÊutica, e, uso de uma composiÇço farmacÊutica
MX2007007328A (es) * 2004-12-22 2007-07-25 Memory Pharm Corp Ligandos del receptor alfa-7 nicotinico y preparacion y sus usos.
US8093269B2 (en) 2005-06-07 2012-01-10 University Of Florida Research Foundation Alpha 7 nicotinic receptor selective ligands
ATE482959T1 (de) 2005-08-22 2010-10-15 Targacept Inc Heteroarylsubstituierte diazatricycloalkane, verfahren zu deren herstellung und deren anwendung
BRPI0617534A2 (pt) 2005-09-23 2011-07-26 Memory Pharm Corp Composto, composição farmacêutica, método para a ativação/estimulação seletiva de receptores nicotínicos de a-7 em um paciente, método para o tratamento de um paciente que sofre de uma doença psicótica, uma doença neurodegenerativa que envolve uma disfunção do sistema colinérgico, e/ou uma condição de degeneração da memória e/ou da cognição, método para o tratamento de um paciente que sofre de demência e/ou uma outra condição com perda da memória, método para o tratamento de um paciente que sofre de degeneração da memória devida à degeneração cognitiva suave devida ao envelhecimento, mal de alzheimer, esquizofrenia, mal de parkinson, mal de huntington, mal de pick, mal de creutzfeldt-jakob, depressão, envelhecimento, trauma na cabeça, acidente vascular cerebral, hipoxia do cns, senilidade cerebral, demência de multiinfarto, hiv e/ou doença cardiovascular, método para o tratamento e/ou a prevenção da demência em um paciente com mal de alzheimer, método para o tratamento de um paciente para a retirada do álcool ou para o tratamento de um paciente com terapia anti-intoxicação, método para o tratamento de um paciente para conferir neuroproteção contra os danos associados com acidentes vasculares cerebrais e isquemia e excitotoxicidade induzida por glutamato, método para o tratamento de um paciente que sofre de vício de nicotina, dor, tontura de fuso horário, obesidade e/ou diabetes, método de indução de um paciente a parar de fumar, método para o tratamento de um paciente que sofre de degeneração cognitiva suave (mci), demência vascular (vad), declínio cognitivo associado com a idade (aacd), amnésia associada com a cirurgia de coração aberto, apreensão cardíaca, anestesia geral, déficits da memória devido à exposição a agentes anestésicos(...)
US8316104B2 (en) * 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
RS52941B (en) * 2008-02-13 2014-02-28 Targacept Inc. A COMBINATION OF ALFA 7 NICOTINE AGONISTS AND ANTIPSYCHOTICS

Also Published As

Publication number Publication date
AU2008283807A1 (en) 2009-02-05
US20110263859A1 (en) 2011-10-27
HUE030387T2 (en) 2017-05-29
AU2008283813A1 (en) 2009-02-05
AU2012203288B2 (en) 2013-08-29
BRPI0814889A2 (pt) 2017-05-23
TW201402116A (zh) 2014-01-16
TW201402117A (zh) 2014-01-16
RU2012140182A (ru) 2014-03-27
CN101784273A (zh) 2010-07-21
RS52743B (en) 2013-08-30
JP6106549B2 (ja) 2017-04-05
CA2694504A1 (en) 2009-02-05
CN101784273B (zh) 2017-01-18
MX2010001293A (es) 2011-02-25
CO6260080A2 (es) 2011-03-22
IL218976A0 (en) 2012-05-31
MY148002A (en) 2013-02-28
US8119659B2 (en) 2012-02-21
JP5358573B2 (ja) 2013-12-04
JP2010535251A (ja) 2010-11-18
CY1113561T1 (el) 2016-06-22
WO2009018505A1 (en) 2009-02-05
EP2484363A1 (en) 2012-08-08
ECSP10010007A (es) 2010-07-30
US20090048290A1 (en) 2009-02-19
TW200914004A (en) 2009-04-01
SA112330303B1 (ar) 2014-11-10
TWI429435B (zh) 2014-03-11
CL2013002226A1 (es) 2013-11-15
PE20090566A1 (es) 2009-05-13
PT2182949E (pt) 2013-02-14
JP2013231071A (ja) 2013-11-14
SA08290475B1 (ar) 2013-06-22
ES2606752T3 (es) 2017-03-27
EP2431037A1 (en) 2012-03-21
AU2012203288A1 (en) 2012-06-21
UY31265A (es) 2009-12-14
KR20100063043A (ko) 2010-06-10
CN103172628A (zh) 2013-06-26
ES2415107T3 (es) 2013-07-24
CO6260081A2 (es) 2011-03-22
PL2182949T3 (pl) 2013-06-28
ZA201000719B (en) 2010-11-24
US20140024673A1 (en) 2014-01-23
PE20121820A1 (es) 2013-01-23
DK2182949T3 (da) 2013-04-02
PE20121821A1 (es) 2013-01-23
US8846715B2 (en) 2014-09-30
US8541446B2 (en) 2013-09-24
EP2431037B1 (en) 2016-11-30
NZ582986A (en) 2012-01-12
HK1140968A1 (es) 2010-10-29
JP2010535252A (ja) 2010-11-18
CA2694510A1 (en) 2009-02-05
ES2611139T3 (es) 2017-05-05
EP2409703A1 (en) 2012-01-25
NZ582828A (en) 2011-09-30
HRP20130286T1 (en) 2013-06-30
ME01508B (me) 2014-04-20
EP2182949A1 (en) 2010-05-12
NO20100078L (no) 2010-02-26
US20150045386A1 (en) 2015-02-12
WO2009018511A2 (en) 2009-02-05
CL2008002271A1 (es) 2008-12-19
BRPI0815009A2 (pt) 2015-03-03
EP2182949B1 (en) 2013-01-02
EP2185152A2 (en) 2010-05-19
DK2431037T3 (en) 2017-02-13
US20110124678A1 (en) 2011-05-26
JP5852611B2 (ja) 2016-02-03
CN106831755A (zh) 2017-06-13
AU2008283807B2 (en) 2012-03-29
EP2465501A1 (en) 2012-06-20
JP2013231070A (ja) 2013-11-14
US7981906B2 (en) 2011-07-19
CL2013002227A1 (es) 2013-11-08
WO2009018511A3 (en) 2009-04-23
RU2012140148A (ru) 2014-03-27
AR067775A1 (es) 2009-10-21
ECSP10010008A (es) 2010-04-30
CN101868237A (zh) 2010-10-20
CA2694504C (en) 2014-01-07
MX346451B (es) 2017-03-17
EP2465501B1 (en) 2016-10-05
NO20100077L (no) 2010-02-26
US20120129885A1 (en) 2012-05-24
SI2182949T1 (sl) 2013-10-30
KR20100051684A (ko) 2010-05-17

Similar Documents

Publication Publication Date Title
MX346451B (es) (2s, 3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)ben zofuran-2-carboxamida, formas salinas novedosas, y sus metodos de uso.
UA105204C2 (en) (2s,3r)-n-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide and therapeutic use tereof
WO2012003418A3 (en) Functionally selective ligands of dopamine d2 receptors
MY158339A (en) DIAMIDE COMPOUNDS HAVING MUSCARING RECEPTOR ANTAGONIST AND ß2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
MX2009012749A (es) Compuestos heterociclicos como moduladores positivos del receptor de glutamato metabotropico 2 (receptor mglu2).
GEP20125566B (en) Aryl-and heteroaryl-substituded tetrahydro-benzazepines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
TW200801013A (en) Substituted benzofused derivatives and their use as vanilloid receptor ligands
WO2006105117A3 (en) Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
MX2010004494A (es) Uso de anticuerpos de trkb para el tratamiento de trastornos respiratorios.
MX355142B (es) Acetamidas heterociclicas sustituidas como agonistas del receptor opioide kappa (kor).
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
WO2008045371A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists
MX2010005648A (es) Derivados de alcano azabiciclico sustituidos con biarilo como moduladores de la actividad del receptor nicotinico de acetilcolina.
MX2010002899A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de la histamina-3.
MX2010002760A (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3.
MY180581A (en) A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof
PT1853232E (pt) Forma cristalina estável de mesilato de bifeprunox, suas formas de dosagem e métodos para a sua utilização
MX368459B (es) Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
TW200642690A (en) Composition for treating central nervous system disorders
WO2007136741A3 (en) N-desmethyl-doxepin and methods of using the same to treat sleep disorders
WO2012012410A3 (en) Kappa opioid receptor agonists
SE0401465D0 (sv) New substituted piperdines as modulators of dopamine neurotransmission
UA100026C2 (en) (2s,3r)-n-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide and salt forms thereof